It would be of interest to determine whether HDL enriched in SAA1 and depleted of ApoA1, as seen in patients with COVID-19 and other inflammatory diseases, may exhibit an altered ability to modify SARS-CoV-2 infection of target cells. This evidence concerns the gene SAA1 and COVID-19.